A panelist discusses a typical lower-risk myelodysplastic syndrome case managed with luspatercept over ...

The myelodysplastic syndromes (MDS) are disorders of the haematopoietic stem cells in the bone marrow, that result in a decreased production of blood cells. MDS mainly affects patients aged 70 and ...

Nature Immunology - Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohydrotic ectodermal dysplasia Skip to main content Thank you for visiting nature.com.

Bristol Myers Squibb has announced positive topline results from its phase 3 trial of Reblozyl (luspatercept-aamt), the first erythroid maturation agent for first-line treatment of patients with ...